Bluebird CEO defends $1.8 million gene therapy price — ‘It’s really thinking about it differently’

Bluebird Bio's $ 1.8 million gene therapy, Zynteglo, is the second most expensive drug in the world behind Novartis' $ 2.1 million gene therapy for spinal muscular atrophy. Health and Science U.S.HEALTHCARE UPDATE: Click today to request your free ACRX…